Cocrystal Pharma, Inc.
COCPNASDAQHealthcare● Active
$1.01
+$0.05(+4.74%)
Market Cap$10351957
P/E Ratio—
52W High$2.67
52W Low$0.86
Cocrystal Pharma, Inc. (COCP) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
COCP · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 21, 2026EPS Actual
-$0.16
Est. -$0.15 · -6.7%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 21, 2026
After Market Close
▼ Miss EPS
COCP reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$0.17 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 21, 2026 | -$0.15 | -$0.16 | -6.7% | — | — | — |
| ▼ Q2 FY2026 | May 15, 2026 | -$0.15 | -$0.17 | -13.3% | $0.00B | $0.00B | -55.6% |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$0.22 | -$0.19 | +13.6% | — | — | — |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$0.30 | -$0.20 | +33.3% | — | — | — |
| ▲ Q2 FY2025 | May 15, 2025 | -$0.52 | -$0.23 | +55.8% | — | — | — |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$0.55 | -$0.32 | +41.8% | $0.00B | — | — |
| ▲ Q4 FY2024 | Nov 13, 2024 | -$0.57 | -$0.49 | +14.0% | — | — | — |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$0.17
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 21, 2026Miss
EPS Actual
-$0.16
EPS Est.
-$0.15
EPS Surpr.
-6.7%
Revenue
—
Q2 FY2026
May 15, 2026Miss
EPS Actual
-$0.17
EPS Est.
-$0.15
EPS Surpr.
-13.3%
Revenue
$0.00B
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$0.19
EPS Est.
-$0.22
EPS Surpr.
+13.6%
Revenue
—
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$0.20
EPS Est.
-$0.30
EPS Surpr.
+33.3%
Revenue
—
Q2 FY2025
May 15, 2025Beat
EPS Actual
-$0.23
EPS Est.
-$0.52
EPS Surpr.
+55.8%
Revenue
—
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
-$0.32
EPS Est.
-$0.55
EPS Surpr.
+41.8%
Revenue
$0.00B
Q4 FY2024
Nov 13, 2024Beat
EPS Actual
-$0.49
EPS Est.
-$0.57
EPS Surpr.
+14.0%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.18 | $-0.18 | $-0.18 | 1 |
| Q3 FY2026 | $-0.18 | $-0.17 | $-0.16 | 2 |
| Q2 FY2026 | $-0.17 | $-0.17 | $-0.15 | 2 |
| Q1 FY2026 | $-0.16 | $-0.15 | $-0.14 | 2 |
| Q4 FY2025 | $-0.17 | $-0.17 | $-0.17 | 2 |
| Q3 FY2025 | $-0.21 | $-0.21 | $-0.21 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 21, 2026 | -6.7% | $1.11 | $1.13 | +1.80% |
| ▼ Q2 FY2026 | May 15, 2026 | -13.3% | $1.26 | $1.20 | -4.76% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +13.6% | $1.03 | $1.03 | +0.00% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +33.3% | $1.68 | $1.68 | +0.00% |
| ▲ Q2 FY2025 | May 15, 2025 | +55.8% | $1.46 | $1.44 | -1.37% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +41.8% | $1.48 | $1.42 | -4.05% |
| ▲ Q4 FY2024 | Nov 13, 2024 | +14.0% | $1.76 | $1.77 | +0.57% |
| ▼ Q3 FY2024 | Aug 14, 2024 | -3.9% | $1.90 | $1.70 | -10.53% |
Q2 FY2026+1.80%
Report Date
May 21, 2026
EPS Beat/Miss
-6.7%
Price Before
$1.11
Price After
$1.13
Q2 FY2026-4.76%
Report Date
May 15, 2026
EPS Beat/Miss
-13.3%
Price Before
$1.26
Price After
$1.20
Q4 FY2025+0.00%
Report Date
Nov 14, 2025
EPS Beat/Miss
+13.6%
Price Before
$1.03
Price After
$1.03
Q3 FY2025+0.00%
Report Date
Aug 14, 2025
EPS Beat/Miss
+33.3%
Price Before
$1.68
Price After
$1.68
Q2 FY2025-1.37%
Report Date
May 15, 2025
EPS Beat/Miss
+55.8%
Price Before
$1.46
Price After
$1.44
Q1 FY2025-4.05%
Report Date
Mar 31, 2025
EPS Beat/Miss
+41.8%
Price Before
$1.48
Price After
$1.42
Q4 FY2024+0.57%
Report Date
Nov 13, 2024
EPS Beat/Miss
+14.0%
Price Before
$1.76
Price After
$1.77
Q3 FY2024-10.53%
Report Date
Aug 14, 2024
EPS Beat/Miss
-3.9%
Price Before
$1.90
Price After
$1.70
Avg Beat Reaction-0.97%
Avg Miss Reaction-4.50%
Beat Rate5 / 8 quarters
Largest Move-10.53% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: COCP ends December
Cocrystal Pharma, Inc. (COCP) most recently reported earnings on May 21, 2026 for Q2 FY2026, posting EPS of $-0.16 — missing the analyst consensus of $-0.15 by -6.7%. The next COCP earnings date is expected around September 1, 2026.
Each quarter, investors track COCP earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. COCP revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
COCP's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
COCP earnings · 5 questionsCocrystal Pharma, Inc.'s next earnings report is expected around September 1, 2026. COCP typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; COCP historically reports after market close (AMC).
COCP earnings datewhen is COCP earningsCOCP next earnings datewhen does COCP report earningsCOCP earnings calendar
▸ Source: FMP · Cocrystal Pharma, Inc. SEC filings · US GAAP · Cocrystal Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026